Core Insights - Repligen is recognized as one of the few publicly traded pure-play bioprocessing companies, highlighting its unique market position and innovation history [2] Group 1: Q3 Recap - The discussion includes a recap of Q3 performance and its implications for future momentum [3] Group 2: Future Framework - The company is focusing on a framework for the upcoming year, building on insights from the Q3 call [4] - Long-term growth drivers will be discussed, including ATF and additional factors beyond that [4]